LEADER 01409nam  2200385Ia 450 
001 9910696927803321
005 20230902161715.0
035   $a(CKB)5470000002383616
035   $a(OCoLC)557250072
035   $a(EXLCZ)995470000002383616
100   $a20100317d2000      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $ewaiver of in vivo bioavailability studies for immediate-release soild oral dosage forms based on a biopharmaceutics classification system
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2000]
215   $a1 electronic resource (13 pages)
300   $a"BP."
300   $a"August 2000."
517   $aGuidance for industry 
606   $aDrugs$xDosage forms$xBioavailability$zUnited States
606   $aDrugs$zUnited States$xTherapeutic equivalency
606   $aBiopharmaceutics
615  0$aDrugs$xDosage forms$xBioavailability
615  0$aDrugs$xTherapeutic equivalency.
615  0$aBiopharmaceutics.
712 02$aCenter for Drug Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910696927803321
996   $aGuidance for industry$93434577
997   $aUNINA